Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), Actinium Pharmaceuticals

Conditions

Acute LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseAllogeneic DiseaseEngraftment SyndromeGraft-Versus-Host DiseaseLeukemia

Phase 2

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

TerminatedNCT00074490

National Cancer Institute (NCI)Leukemia, Lymphoma, Multiple Myleoma +2

Start: 2004-01-01End: 2017-08-16Updated: 2018-12-31

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

CompletedNCT00923845

National Cancer Institute (NCI)Engraftment Syndrome, Graft-Versus-Host Disease, Renal Cell Carcinoma

Start: 2008-03-01End: 2017-06-22Updated: 2017-09-29

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Not yet recruitingNCT07157514

Actinium PharmaceuticalsAcute Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia +8

Start: 2026-01-31End: 2034-02-28Target: 306Updated: 2025-09-10

Related Papers

Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease

Blood2015-12-033 citations